Irene Becklund Sells 943 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 943 shares of the company’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $14.50, for a total transaction of $13,673.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Irene Becklund also recently made the following trade(s):

• On Monday, March 18th, Irene Becklund sold 472 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.70, for a total transaction of $6,938.40.
• On Thursday, March 7th, Irene Becklund sold 2,747 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.19, for a total value of $38,979.93.
• On Tuesday, February 27th, Irene Becklund sold 2,747 shares of Hims & Hers Health stock. The stock was sold at an average price of $12.08, for a total value of $33,183.76.

Hims & Hers Health Stock Down 5.6 %

Shares of HIMS stock opened at $17.55 on Wednesday. The stock has a market cap of $3.77 billion, a PE ratio of -1,755.00 and a beta of 0.97. Hims & Hers Health, Inc. has a 52-week low of $5.65 and a 52-week high of $20.11. The business has a 50-day simple moving average of $14.06 and a 200-day simple moving average of $10.97.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.05) EPS. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.18 earnings per share for the current fiscal year.

Institutional Trading of Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Forerunner Ventures Management LLC purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth about $86,836,000. M&G Plc acquired a new stake in Hims & Hers Health in the first quarter valued at approximately $8,232,000. Vanguard Group Inc. increased its position in shares of Hims & Hers Health by 3.1% in the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after buying an additional 428,671 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Hims & Hers Health by 39.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,272,750 shares of the company’s stock worth $8,006,000 after buying an additional 357,590 shares during the period. Finally, Federated Hermes Inc. lifted its position in shares of Hims & Hers Health by 38.6% during the 3rd quarter. Federated Hermes Inc. now owns 1,032,452 shares of the company’s stock valued at $6,494,000 after buying an additional 287,552 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of recent analyst reports. Jefferies Financial Group restated a “hold” rating and issued a $15.00 price target (down from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Imperial Capital upgraded Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price objective for the company in a report on Wednesday, February 28th. Citigroup boosted their target price on Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Guggenheim raised their price target on Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, Seaport Res Ptn restated a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.08.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.